U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275840) titled 'A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD' on Nov. 24.
Brief Summary: This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Study Start Date: Dec. 09
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-related Macular Degeneration
Intervention:
DRUG: IBI302 8mg dose
8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Innovent Bio...